Prescription psychostimulants for cocaine use disorder: A review from molecular basis to clinical approach
Addiction Biology · 2023-04 · 28 (4)
DOI: 10.1111/adb.13271 ↗At a glance
Übersichtsarbeit in Addiction Biology, 2023-03. Written by Vitor S Tardelli and 5 co-authors. Institution: Departamento de Psiquiatria, Universidade Federal de Sao Paulo (Unifesp), Sao Paulo, SP, Brazil. Major MEDLINE topics: Cocaine-Related Disorders, Central Nervous System Stimulants, Prescription Drugs. Cited 12 times so far (Crossref); 89 references. The full text is freely available in PubMed Central. Funded by: NIDA NIH HHS, National Institutes of Health, New York State Psychiatric Institute.
Abstract (original language)
Cocaine use is a public health concern in many countries worldwide, particularly in the Americas and Oceania. Overdose deaths involving stimulants, such as cocaine, have been increasing markedly in North America, especially with concurrent opioid involvement. To date, no pharmacological treatment is available to treat stimulant (including cocaine) use disorders. Prescription psychostimulants (PPs) could be useful to treat cocaine use disorder (CUD) as they share the pharmacological effects with cocaine, as evidenced by a recent meta‐analysis that assessed 38 randomized clinical trials (RCTs). PPs were found to promote sustained abstinence and reduce drug use in patients with CUD. The aim of this paper is to provide a narrative review of the clinical pharmacology of PPs and comment on the current stage of evidence supporting PPs to treat CUD. We also propose a model of care that integrates PPs with evidence‐based psychosocial interventions (such as cognitive‐behavioural therapy [CBT] and contingency management [CM]), a harm reduction approach and case management with social support.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Departamento de Psiquiatria, Universidade Federal de Sao Paulo (Unifesp), Sao Paulo, SP, Brazil.
- Translational Addiction Research Laboratory, Center for Addiction and Mental Health, Toronto, ON, Canada.
- Department of Psychiatry and Human Behavior, University of Mississipi Medical Center, Jackson, MS, USA.
- Mental Health Department, Azienda Unitá Sanitaria Locale, Parma, Italy.
- The Department of Psychiatry, Vagelos College of Physicians and Surgeons, Columbia University and the New York State Psychiatric Institute, New York, NY, USA.
- Young Leaders Program from the National Academy of Medicine, Brazil.
ORCID profiles: Vitor S Tardelli, Lais F Berro
Funding
- NIDA NIH HHS
- National Institutes of Health
- New York State Psychiatric Institute
Cite
APA
Tardelli, V. S., Berro, L. F., Gerra, G., Tadonio, L., Bisaga, A., & Fidalgo, T. M. (2023). Prescription psychostimulants for cocaine use disorder: A review from molecular basis to clinical approach. Addiction Biology, 28(4). https://doi.org/10.1111/adb.13271
Vancouver
Tardelli VS, Berro LF, Gerra G, Tadonio L, Bisaga A, Fidalgo TM. Prescription psychostimulants for cocaine use disorder: A review from molecular basis to clinical approach. Addiction Biology. 2023;28(4). doi:10.1111/adb.13271
BibTeX
@article{Tardelli2023,
author = {Tardelli, Vitor S and Berro, Lais F and Gerra, Gilberto and Tadonio, Leonardo and Bisaga, Adam and Fidalgo, Thiago M},
title = {Prescription psychostimulants for cocaine use disorder: A review from molecular basis to clinical approach},
journal = {Addiction Biology},
year = {2023},
volume = {28},
number = {4},
doi = {10.1111/adb.13271}
}
EUVIMED